Michael Barbella, Managing Editor06.30.22
ENDRA Life Sciences Inc. has been issued a new U.S. patent related to its Thermo Acoustic Enhanced UltraSound (TAEUS) System.
U.S. Patent No. 11337676, titled “Acoustically Compatible Radio-frequency Applicator Method and System,” protects ENDRA's method and system for optimizing the delivery of radiofrequency (RF) energy to tissue using TAEUS, and serves as the parent patent for applications used in China and in Europe.
“This issued patent is our 27th in the United States and supports our strategy to develop optimized hybrid ultrasound and thermoacoustic imaging systems and to broaden the potential applications for our proprietary TAEUS technology in areas with unmet clinical needs," ENDRA Chairman and CEO Francois Michelon said. "We continue to enhance our intellectual property portfolio to protect our technology in priority global markets. Our IP portfolio currently stands at 90 assets, including 47 patents issued globally.”
ENDRA Life Sciences developed TAEUS, a technology to visualize tissue like MRI, but at 1/50 th the cost and at the point of patient care. TAEUS is designed to work in concert with more than 500,000 ultrasound systems in use globally today. TAEUS is initially focused on measuring liver fat as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect more than 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including tissue temperature visualization during energy-based surgical procedures.
U.S. Patent No. 11337676, titled “Acoustically Compatible Radio-frequency Applicator Method and System,” protects ENDRA's method and system for optimizing the delivery of radiofrequency (RF) energy to tissue using TAEUS, and serves as the parent patent for applications used in China and in Europe.
“This issued patent is our 27th in the United States and supports our strategy to develop optimized hybrid ultrasound and thermoacoustic imaging systems and to broaden the potential applications for our proprietary TAEUS technology in areas with unmet clinical needs," ENDRA Chairman and CEO Francois Michelon said. "We continue to enhance our intellectual property portfolio to protect our technology in priority global markets. Our IP portfolio currently stands at 90 assets, including 47 patents issued globally.”
ENDRA Life Sciences developed TAEUS, a technology to visualize tissue like MRI, but at 1/50 th the cost and at the point of patient care. TAEUS is designed to work in concert with more than 500,000 ultrasound systems in use globally today. TAEUS is initially focused on measuring liver fat as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect more than 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including tissue temperature visualization during energy-based surgical procedures.